關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

LabConnect Appoints Bill Finger as Senior Vice President, Global Strategic Services

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 375 加入收藏 :

JOHNSON CITY, Tenn., Sept. 19, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Bill Finger as Senior Vice President, Global Strategic Services, effective Wednesday, September 10, 2025. 

Bill brings more than 25 years of diagnostics and clinical research experience, with deep expertise in the global lab and pharmacy industry. As a senior executive, he is recognized as an innovative thinker with a proven ability to develop strategy, drive execution, and advance organizational performance while maintaining a sharp focus on operational excellence.   

Most recently, Bill served as Vice President and General Manager, Pharma Services with Quest Diagnostics. Prior to that, he was Chief Operating Officer for Interpace Pharma Solutions, Executive Vice President of Precision Medicine and Pharma for Cancer Genetics, and held leadership roles in scientific affairs and biorepository with LabCorp.   

In his new role, Bill will lead LabConnect's Scientific Services, Consulting Services, Data Management, and Functional Service Provider (FSP) teams.  

"Bill's leadership in diagnostic and clinical research is a tremendous asset to LabConnect," said Wes Wheeler, LabConnect CEO. "His experience will ensure we continue to anticipate client needs, deliver innovative solutions, and reinforce our commitment to operational excellence for our clients around the world."

For more information about LabConnect, please visit www.LabConnect.com.

About LabConnect
LabConnect is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases.

LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.

Learn more at www.labconnect.com and follow on LinkedIn.

Logo - https://mma.prnasia.com/media2/2611513/LabConnect_Logo.jpg?p=medium600

以上新聞投稿內容由 PR Newswire 美通社 全權自負責任,若有涉及任何違反法令、違反本網站會員條款、有侵害第三人權益之虞,將一概由 PR Newswire 美通社 承擔法律及損害賠償之責任,與台灣產經新聞網無關。

Tags :
2025 年 11 月 11 日 (星期二) 農曆九月廿二日
首 頁 我的收藏 搜 尋 新聞發佈